Based on the current sales trend for DefenCath as well as the performance of the recently acquired Melinta portfolio, CorMedix (CRMD) is increasing its full-year 2025 pro forma net revenue guidance from the previously announced range of $325-$350 million to at least $375 million(1).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRMD:
- CorMedix files to sell 6.32M shares of common stock for holders
- Largest borrow rate increases among liquid names
- CorMedix completes enrollment in Phase III ReSPECT trial for REZZAYO
- Cormedix’s Strategic Growth: Melinta Acquisition and Rezzayo’s Market Expansion Justify Buy Rating
- Cormedix’s Positive Outlook: Buy Rating Backed by Strong Sales Guidance and Strategic Initiatives